Cost-effectiveness of prevention program for type 2 diabetes mellitus in high risk patients in the Republic of Srpska, Bosnia and Herzegovina

被引:0
|
作者
Grujic-Vujmilovic, Dragana [1 ,2 ]
Veljkovic, Kristina [3 ]
Gavric, Zivana [1 ,2 ]
Popovic-Pejicic, Snjezana [4 ,5 ]
机构
[1] Univ Banja Luka, Fac Med, Dept Social Med, Banja Luka, Republic Of Srp, Bosnia & Herceg
[2] Publ Hlth Inst Republ Srpska, Dept Social Med, Banja Luka, Republic of Srp, Bosnia & Herceg
[3] Univ Ljubljana, Fac Comp & Informat Sci, Lab Cryptog & Comp Secur, Vecna Pot 113, Ljubljana 1000, Slovenia
[4] Univ Banja Luka, Fac Med, Dept Internal Med, Banja Luka, Republic Of Srp, Bosnia & Herceg
[5] Univ Clin Ctr Republ Srpska, Banja Luka, Republic Of Srp, Bosnia & Herceg
关键词
Cost-effectiveness; Markov chain model; FINDRISC; prevention; impaired glucose tolerance; type 2 diabetes mellitus; GLUCOSE-TOLERANCE; CARDIOVASCULAR EVENTS; SCREENING-PROGRAM; UTILITY VALUES; MORTALITY; DISEASE; FOOT; LIFE; COMPLICATIONS; PROGRESSION;
D O I
10.1080/19932820.2024.2437226
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Republic of Srpska (RS), as a part of the Western Balkans (WB) region, has a higher diabetes prevalence than the EU. This study aims to assess the cost-effectiveness of early treatment of high-risk patients with pre-diabetes and undiagnosed diabetes in our setting. We designed a Markov chain Monte Carlo (MCMC) model which reflects the current International Diabetes Federation (IDF) three-step plan for the prevention of T2DM in those at increased risk. The model captures the evolution of the disease in FINDRISC high-risk patients from normal glucose tolerance (NGT) to impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) and then to T2DM and its complications. We developed two MCMC models, in order to follow the progression of the disease in high-risk cases, ie, when early treatment is undertaken or when it is not undertaken. The health costs and quality adjusted life years (QALY) were discounted at an annual rate of 3%. The key model parameters were varied in one-way and probabilistic sensitivity analysis. Early treatment resulted in increased life expectancy, postponement of the onset of diabetes and increased QALY for all patients. The discounted incremental cost-effectiveness-ratios (ICER) in NGT, IFG, IGT, and T2DM patients were -289.9, 9724.03, -1478.59 and 4084.67 <euro>. In high-risk IGT patients, ICER was the most favorable, being both a cost saving and QALY gaining, with the consistent results confirmed by the sensitivity analysis. The results recommend the acceptance of a new health policy of identifying IGT patients with the use of FINDRISC questionnaire and plasma glucose measurements; providing them with a lifestyle change program; and implementing intensive diabetes treatment, as their disease progresses. Our results are especially significant for the Western Balkan countries, since this was the first cost-effectiveness study of T2DM prevention in this region.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
    Vega-Hernandez, Gabriela
    Wojcik, Radek
    Schlueter, Max
    DIABETES THERAPY, 2017, 8 (03) : 513 - 530
  • [42] Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
    Gabriela Vega-Hernandez
    Radek Wojcik
    Max Schlueter
    Diabetes Therapy, 2017, 8 : 513 - 530
  • [43] DAPAGLIFLOZIN VERSUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN COLOMBIA: COST-EFFECTIVENESS ANALYSIS
    Ordonez, J. E.
    VALUE IN HEALTH, 2017, 20 (05) : A172 - A172
  • [44] Cost-effectiveness analysis of the diabetes prevention program in a Spanish setting
    Palmer, AJ
    Roze, S
    Valentine, WJ
    Renaudin, C
    VALUE IN HEALTH, 2004, 7 (06) : 741 - 741
  • [45] Cost-effectiveness of SHINE: A Telephone Translation of the Diabetes Prevention Program
    Hollenbeak, Christopher S.
    Weinstock, Ruth S.
    Cibula, Donald
    Delahanty, Linda M.
    Trief, Paula M.
    HEALTH SERVICES INSIGHTS, 2016, 9
  • [46] DOES THE APPLICATION OF UKPDS RISK EQUATIONS UNDERESTIMATE THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN TYPE 2 DIABETES MELLITUS?
    McEwan, P.
    Bennett, H.
    Kartman, B.
    Edmonds, C.
    Gause-Nilsson, I
    Wilding, J.
    VALUE IN HEALTH, 2019, 22 : S581 - S581
  • [47] COST-EFFECTIVENESS OF STATINS FOR PRIMARY PREVENTION IN NEWLY DIAGNOSED TYPE 2 DIABETES PATIENTS IN THE NETHERLANDS
    de Vries, F. M.
    Denig, P.
    Visser, S. T.
    Hak, E.
    Postma, M. J.
    VALUE IN HEALTH, 2013, 16 (07) : A526 - A526
  • [48] Cost-Effectiveness of Statins for Primary Prevention in Patients Newly Diagnosed with Type 2 Diabetes in The Netherlands
    de Vries, Folgerdiena M.
    Denig, Petra
    Visser, Sipke T.
    Hak, Eelko
    Postma, Maarten J.
    VALUE IN HEALTH, 2014, 17 (02) : 223 - 230
  • [49] COST-EFFECTIVENESS OF COMMUNITY PHARMACISTS' INTERVENTION FOR PATIENTS WITH TYPE 2 DIABETES IN PREVENTION OF DIABETIC RETINOPATHY
    Shoji, M.
    Onda, M.
    Okada, H.
    Sakane, N.
    Nakayama, T.
    VALUE IN HEALTH, 2017, 20 (09) : A479 - A480
  • [50] Risk factor indicators in offspring of patients with premature coronary heart disease in Banja Luka region/Republic of Srpska/Bosnia and Herzegovina
    Vulic, Dusko
    Loncar, Sasa
    Ostojic, Miodrag
    Marinkovic, Jelena
    Vulic, Branka
    Wong, Nathan D.
    ARCHIVES OF MEDICAL SCIENCE, 2016, 12 (04) : 736 - 741